ArticleFrontiers in pharmacology2025
Medication use in Poland for children and adolescents with neurodevelopmental disorders: before, during and after the COVID-19 pandemic - a retrospective pharmacoepidemiological study using national reimbursement data.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood.Pharmacoepidemiology and drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pandemic profoundly disrupted healthcare and education systems, potentially affecting the pharmacological management of neurodevelopmental disorders (NDDs) in children and adolescents. Objective: To examine national trends in psychotropic drug dispensing among pediatric patients with NDDs in Poland before, during, and after the COVID-19 pandemic. Methods: A retrospective pharmacoepidemiological analysis was conducted using data from the IQVIA Pharmascope database, which records all reimbursed medicines dispensed by community pharmacies in Poland. Monthly and annual dispensing volumes were analyzed for January 2018-December 2024, focusing on drugs commonly used in ADHD, autism spectrum disorder, and intellectual disability. Three time periods were compared: pre-pandemic (2018-February 2020), pandemic (March 2020-June 2022), and post-pandemic (July 2022-December 2024). Results: A marked surge in psychotropic drug dispensing was observed in 2021, with total annual utilization jumping to nearly 2.7 billion dispensed days of therapy (DOT)-more than double the levels seen in any prior year. This represents a 161% increase compared with 2020, when volumes were approximately 1.0 billion DOT. The most substantial increases occurred for sedative and anxiolytic agents (hydroxyzine, diazepam, alprazolam, lorazepam) and antipsychotics (olanzapine, aripiprazole, risperidone, chlorprothixene, haloperidol, levomepromazine), consistent with pandemic related stress, limited access to non-pharmacological care, and possible stockpiling. Dispensing volumes fell sharply in 2022 to around 1.1 billion DOT, returning close to pre-pandemic levels and suggesting these effects were transient. A modest upward trend resumed thereafter, with volumes rising to approximately 1.2 billion DOT in 2023 and 1.5 billion DOT in 2024, indicating gradual recovery but remaining far below the extraordinary 2021 peak. Conclusion: The COVID-19 pandemic induced broad but temporary increases in pediatric psychotropic drug dispensing, except for ADHD pharmacotherapies, which demonstrated a persistent upward trend. These findings suggest lasting shifts in diagnostic and therapeutic practices and underscore the need for continued monitoring of stimulant use and prescribing appropriateness in pediatric neurodevelopmental care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.